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Background: Progressive multifocal leukoencephalopathy (PML), a rare but fatal demyelinating disease caused
by JC virus (JCV), occurs mainly in immunocompromised patients. As PML develops in individuals with various
underlying disorders sporadically and infrequently, a nationwide survey of PML is difficult. This study was conducted
to elucidate the characteristics of PML in Japan through an internet-assisted laboratory surveillance program.
Methods: A diagnostic support system for PML was established using a real-time PCR assay of JCV DNA in
cerebrospinal fluid (CSF), and requests for testing were received from clinicians via specialized websites. Medical
histories of patients were collected through standardized questionnaires, and a database of CSF JCV loads and
clinical information was created and analyzed.
Results: For 4 years from April 2007 to March 2011, CSF specimens from 419 patients were tested. Forty-eight
individuals were found positive for JCV DNA in their CSF and were diagnosed with PML. PML primarily occurred
not only in HIV-positive patients (33.3%) but also in patients with hematologic disorders after receiving stem cell
transplantation, chemotherapy, and/or immunosuppressive treatment (39.6%). The frequencies of PML cases among
the subjects in these two categories were 20.3% and 23.5%, respectively. Although no significant features were
observed with respect to CSF JCV loads in PML patients with an HIV infection or hematologic disorder, males were
predominant in both groups (100% and 89.5%, respectively). The proportion of PML cases with autoimmune
disorders (6.3%) or solid-organ transplants (2.1%) was smaller than those with HIV infection or hematologic
disorders, probably due to the limited availability of therapeutic monoclonal antibodies and transplantation
from brain dead donors.
Conclusions: The results suggest that the internet-assisted laboratory surveillance program might be a useful
strategy for collecting precise real-time information on PML on a national level. The current database provides
important background information for the diagnosis and treatment of patients with risk factors for PML.
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Progressive multifocal leukoencephalopathy (PML) is a
rare but fatal demyelinating disease caused by JC virus
(JCV), a small DNA virus belonging to the family
Polyomaviridae, genus Polyomavirus [1-3]. JCV estab-
lishes a persistent and asymptomatic infection in a large
number of individuals, with the serologically positive
rate for JCV among the adult human population being
50–90%. However, in some severely immunocom-
promised patients, JCV reactivates and causes a lytic
infection in the oligodendrocytes, leading to PML [1-4].
PML develops in human immunodeficiency virus (HIV)-
positive patients as well as in those with immunodefi-
ciency due to hematological malignancies, chemotherapy,
transplantation, lymphocyte depletion or autoimmune
disorders, such as systemic lupus erythematosus (SLE),
treated with immunosuppressive agents [1-4]. In addi-
tion, PML has recently been diagnosed in patients receiving
immunomodulatory therapies with monoclonal antibodies,
such as natalizumab, rituximab, and efalizumab [2,5].
To conduct a nationwide survey of PML, the collec-
tion and analysis of large amounts of clinical data are
necessary. However, as PML develops in patients with
various underlying disorders sporadically and infre-
quently, a comprehensive surveillance of PML is diffi-
cult. Recent epidemiological data on PML were mainly
obtained from retrospective cohort studies of HIV-
infected persons [6-15] or reported cases of serious
adverse events following treatment with monoclonal
antibodies [16-23]. Although the results of these investi-
gations are important for a better understanding of PML
in association with HIV infection or monoclonal anti-
body therapies, it is difficult to comprehensively monitor
PML patients with diverse underlying diseases. Several
other recent studies demonstrated the incidence of
PML using national databases in the USA, such as the
National Multiple Cause of Death Data system, the
Nationwide Inpatient Sample, the US health insurance
claims database, and the US Renal Data System [24-27].
While these database screening strategies are considered
to be beneficial for the surveillance of PML, the amount
of information available for each case is limited.
The detection of JCV DNA in cerebrospinal fluid
(CSF) by PCR is a reliable and less-invasive marker for
the diagnosis of PML [1]. In Japan, the ongoing CSF
testing for JCV DNA has been supported by the Labo-
ratory of Neurovirology, Department of Virology 1,
National Institute of Infectious Diseases (NIID), Tokyo,
Japan, since April 2007. Through this practice, datasets
of clinical information are being obtained not only from
PML patients but also from individuals suspected of
having PML via their physicians. The current study has
been undertaken to assess the occurrence and character-
istics of PML patients in Japan over the past 4 years.Methods
Clinical information on patients from whom CSF
specimens were collected
This study was performed under informed consent from
patients or their family members and with the approval
of the Ethical Committee for Biomedical Science in the
NIID. CSF testing for JCV DNA was requested from the
patients’ physicians for the diagnosis or management of
PML primarily via two specialized web sites (available in
Japanese language only), [http://www0.nih.go.jp/vir1/
NVL/Virus1/NVL3%20HP/index11.html] and [http://
prion.umin.jp/pml/virus.html]. This diagnostic support
system was funded by the Japanese government (Research
Committee of Prion Disease and Slow Virus Infection,
the Ministry of Health, Labour and Welfare, Japan) and
performed free of charge to patients. CSF specimens
were collected by lumbar puncture from patients
suspected of having PML on the basis of neurological
symptoms and/or magnetic resonance imaging (MRI)
patterns, and were transferred to the NIID. Patient infor-
mation including age, sex, underlying disease, and past
medical history was collected anonymously through stan-
dardized questionnaires.
Real-time PCR testing for JCV DNA
Total DNAs were extracted from CSF specimens using a
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA)
and subjected to real-time PCR assay as described pre-
viously [28]. The pBR322-based plasmid pJC1-4->pJCV
containing the complete genome sequence of JCV
Mad-1 strain [29] was supplied by the Health Science
Research Resources Bank (Osaka, Japan) and was used
as the standard DNA for real-time PCR. For clinical test-
ing of JCV DNA in CSF specimens, three different real-
time PCR assays were developed to detect either the JCV
T or viral protein 1 (VP1) genes and to monitor the
contamination of each clinical sample with standard
DNA. The primers and TaqMan probe targeting the JCV
large T gene were described in an earlier report [28].
A pair of primers (5’- AAT GCA ACA GTG CAA TCT
CA -3’ and 5’- GGC CCA ACA CCA AAT TCA TC -3’)
and a TaqMan probe (5’- TTG GGT TCC TGA TCC
CAC CAG -3’) were designed to detect a highly con-
served region within the JCV VP1 gene. The sequences
of these primers and probes were 100% identical to the
corresponding region of over 360 JCV isolates of various
origins in GenBank (data not shown). To control the
contamination of samples with standard DNA, another
set of primers (5’- CAC AGC TTG ACT GAG GAA -3’
and 5’- GAT GTC GGC GAT ATA GGC -3’) and probe
(5’- ATC CTC TAC GCC GGA CGC AT -3’) were also
designed to detect the boundary sequence of the JCV
genome and pBR322 within pJC1-4->pJCV [see Add-
itional file 1]. This primer/probe set detects standard
Figure 1 The geographical distribution patterns of the
examined population (A) and PML patients (B). All prefectures
are colored based on the number of individuals.
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5’ labeled with 6-carboxyfluorescein and 3’ labeled with
Black Hole Quencher-1. These three PCRs were carried
out independently for each sample under the conditions
described previously [28] except that the annealing
temperature was 58°C instead of 60°C. The copy num-
bers of the viral genome in JCV DNA-positive samples
were determined as reported earlier [28]. In each PCR, tar-
get DNAs were detected in a range from 1 x 109 to 4 cop-
ies per reaction [see Additional file 2] and no
amplification signals were detected, even in the presence
of high concentrations (over 107 copies) of other polyoma-
viruses, including BK virus and simian virus 40 (data
not shown).
Statistical analysis
The proportions of JCV-positive or combination anti-
retroviral therapy (cART)-treated patients in each group
were statistically compared by means of a two-tailed
Fisher's exact test. For multiple testing, the resulting
P-value was corrected using the Benjamini-Hochberg
method [30]. The numbers of clusters of differentiation 4
(CD4)-positive T cells in JCV-positive and -negative
patient groups were compared using a Mann-Whitney U
test. The amounts of CSF JCV DNA in different patient
groups were compared using a Steel-Dwass nonpara-
metric multiple comparison method. All P-values less
than 0.05 were judged to be statistically significant.
Results
Detection of JCV DNA in CSF specimens from patients
From April 2007 to the end of March 2011, 504 CSF spe-
cimens from 419 patients were submitted to the NIID for
testing by hospitals in 43 of Japan’s 47 prefectures (91.5%),
with many requests received from the Tokyo metropolitan
area and other regions with large populations (Figure 1A).
Forty-eight individuals showed a positive reaction for JCV
DNA in the real-time PCR targeting the T and VP1 genes
and were subsequently diagnosed with PML (Figure 1B).
The distribution pattern of PML patients resembled that
of the total population. The PCR testing results and
underlying diseases of the subjects are summarized in
Table 1. Of 48 patients positive for CSF JCV DNA, 16
(33.3%) had HIV infection. The total number of HIV-
positive subjects was 79 (20.3%). The proportion of cART-
received patients found to be positive and negative for
CSF JCV DNA at the initial testing was 31.3% (n = 14)
and 50.8% (n = 57), respectively. The median peripheral
blood CD4 counts in the two groups were 37.0 cells / μL
(n = 13; range, 8–232 cells / μL) and 43.5 cells / μL (n =
60; range, 1–400 cells / μL), respectively. For both para-
meters, no statistical differences were observed between
the JCV-positive and -negative patient groups. Nineteenof the JCV-positive patients (39.6%) had hematologic dis-
orders, and the frequency of PML cases in this cate-
gory was approximately 24%. Of 50 subjects with
autoimmune disorders, 3 with SLE were positive for CSF
JCV. Among patients with other underlying diseases, 9
JCV-positive cases were observed, and high positive ratios
were found among those with lung disease (66.7%) and
sarcoidosis (100%). Among these 4 categories of under-
lying disorders, the proportion of JCV-positive patients
with hematologic disorders, but not that of patients with
HIV infection, was significantly higher than that of
patients with autoimmune disorders (P = 0.009). The
underlying illness of the remaining 1 JCV-positive patient
could not be determined. These results indicate that
PML occurs primarily in patients not only with HIV in-
fection but also with hematologic disorders.Characteristics of PML patients with hematologic
disorders or other underlying diseases
Having shown that PML is frequently seen in patients
with hematologic disorders in Japan, the characteris-
tics of these patients were compared to those of
Table 1 Underlying diseases of patients positive and negative for JCV DNA on the basis of CSF specimens
Underlying disease No. (%) of JCV-positive patients No. (%) of JCV-negative patients
Category Subcategory
HIV infection / AIDS 16 (20.3) 63 (79.7)
Hematologic disorders 19 (23.5) 62 (76.5)
Acute myeloid leukemia 2 (16.7) 10 (83.3)
Acute lymphocytic leukemia 1 (14.3) 6 (85.7)
Chronic myeloid leukemia 0 (0) 2 (100)
Chronic lymphocytic leukemia 1 (50.0) 1 (50.0)
Adult T-cell leukemia 1 (50.0) 1 (50.0)
Hodgkin's lymphoma 1 (50.0) 1 (50.0)
Non-Hodgkin's lymphoma 6 (22.2) 21 (77.8)
Aplastic anemia 2 (50.0) 2 (50.0)
Primary immunodeficiency syndrome 2 (25.0) 6 (75.0)
Multiple myeloma 2 (66.7) 1 (33.3)
Primary macroglobulinemia 1 (100) 0 (0)
Myelodysplastic syndrome 0 (0) 6 (100)
Other 0 (0) 5 (100)
Autoimmune disorders 3 (6.0) 47 (94.0)
Multiple sclerosis 0 (0) 11 (100)
Rheumatoid arthritis 0 (0) 7 (100)
Systemic lupus erythematosus 3 (20.0) 12 (80.0)
Other 0 (0) 17 (100)
Other diseases 9 (10.0) 81 (90.0)
Cerebrovascular disorders 0 (0) 7 (100)
Solid-organ cancer 0 (0) 13 a (100)
Lung diseases 2 (66.7) 1 (33.3)
HCV-related liver disease 3 (37.5) 5 (62.5)
Renal diseases 0 (0) 11 b (100)
Sarcoidosis 3 (100) 0 (0)
Other 1 c (2.2) 44 d (97.8)
None/Unknown 1 (0.8) 118 (99.2)
Total 48 (11.5) 371 (88.5)
HCV, hepatitis C virus.
a Two patients underwent liver transplantation.
b Six patients underwent renal transplantation.
c The patient receiving the liver transplant had common variable immunodeficiency.
d One patient received heart and kidney transplants.
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diseases. The age and sex distributions of study popu-
lation and PML patients are shown in Figure 2. The
majority of subjects and PML patients with HIV infection
were male in their thirties to sixties, and subjects and
PML patients with hematologic disorders or other under-
lying diseases were found at various ages. PML patients
with hematologic disorders were mainly males, while non-
HIV-related PML occurred in both sexes (Figure 2B).
These data suggest that there is a predominance of malesamong PML patients; not only among those with HIV in-
fection but also those with hematologic disorders. The
median viral loads in CSF specimens from patients with
HIV infection, hematologic disorders, and other diseases
were 2.6 x 104, 8.0 x 104, and 6.4 x 103 copies per mL, re-
spectively (Figure 3). No statistical differences in the CSF
JCV levels were found between the groups. These results
indicate that PML cases with hematologic disorders ex-
hibit no significant differences with respect to CSF JCV
loads.
Figure 2 The age and sex distribution patterns of the study population (A) and PML patients (B). The subjects and PML patients were
divided into three groups on the basis of HIV infection, hematologic disorders, or other underlying diseases including autoimmune disorders.
The vertical axes indicate the number of individuals. The solid and open bars show the results for males and females, respectively. The numbers
of below the bars represent 10-year age groups (e.g., “0” indicates individuals aged 0 to 9). The data exclude 1 HIV-positive subject whose age
was not known.
Nakamichi et al. BMC Neurology 2012, 12:121 Page 5 of 9
http://www.biomedcentral.com/1471-2377/12/121Medical history of PML patients with hematologic
disorders
The final set of analyses was conducted to assess the
clinical background of PML patients with hematologic
disorders. The practice of hematopoietic stem cell trans-
plantation (HSCT) in patients found to be positive or
negative for JCV DNA on the basis of CSF specimens is
shown in Table 2. Eight of 19 JCV-positive patients with
hematological disorders (42.1%) received HSCT for the
treatment of acute myeloid leukemia (AML), acute
lymphoblastic leukemia (ALL), Hodgkin’s lymphoma
(HL), non-Hodgkin’s lymphoma (NHL), aplastic anemia
(AA), or multiple myeloma (MM). Among the CSF JCV-
negative cases, 19 of 49 individuals (38.8%) received
HSCT. There was no statistically significant difference in
the proportion of HSCT-treated individuals between the
JCV-positive and -negative patients. The characteristicsof 8 PML patients receiving HSCT are summarized in
Table 3. In these 8 cases, JCV DNA was detected in the
CSF specimens at a median of 471.5 days after trans-
plantation (range, 279–833 days). These results indicate
that in cases of PML with hematologic disorders, a high
proportion of patients had a history of HSCT, and that
PML occurred 1–2 years after the various types of trans-
plantation. However, 11 of 19 PML patients with
hematologic disorders (57.9%) had no record of HSCT.
Thus, potential risk factors for PML were examined in
these patients. Table 4 shows the characteristics of PML
patients without HSCT. Nine of 11 patients (81.8%) were
over 60 years old, and 8 of 11 patients had received
combination chemotherapy, cyclophosphamide or ritu-
ximab. The remaining 3 individuals had no history of
treatment with chemotherapeutic or immunosuppressive
agents, but 2 had primary immunodeficiency syndrome
Figure 3 The JCV DNA levels in the CSF specimens from PML
patients. The CSF viral loads for patients with HIV infection,
hematologic disorders, or other diseases are shown (left to right).
The open circles indicate the copy number of JCV DNA in each
sample, and the horizontal lines represent the medians. In several
cases, JCV DNA measurement was performed for different
specimens from the same patient during the follow-up period.
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cate that PML occurred in patients with hematologic
disorders not only after HSCT but also after treatment
with chemotherapeutic or immunosuppressive drugs.Table 2 Hematopoietic stem cell transplantation (HSCT) in pa
Underlying disease Proportion (%) of JC
patients with HSC
Acute myeloid leukemia 2/2
Acute lymphoblastic leukemia 1/1
Chronic lymphocytic leukemia 0/1









The present study clarified the characteristics of PML
cases in Japan based on clinical data obtained through
the laboratory testing for JCV DNA in CSF specimens.
Mass screening of PML patients has not been feasible in
Japan due to the lack of a suitable database for PML.
The current strategy deals with a relatively small number
of patients but has a distinct advantage in collecting pre-
cise real-time information for patients as well as speci-
mens. The testing was constantly requested by the
physicians via websites, despite the fact that there were
at least 4 commercial laboratories providing similar
assays during the study period according to our own
survey. Thus, this internet-based approach is thought to
be useful for sampling data for rare infectious diseases.
In addition, as this diagnostic support system was con-
ducted regardless of patient age, gender, underlying dis-
ease or medical history, precise information could be
obtained not only from PML patients but also from
CSF-JCV-negative individuals with similar conditions.
These data are considered to be valuable for the examin-
ation of the overall background to PML in Japan.
A large number of PML patients had HIV infection /
acquired immunodeficiency syndrome (AIDS) or he-
matologic disorders. Recent database analyses and other
clinical studies in the USA have suggested that approxi-
mately 79–82% of PML patients are positive for HIV and
7.7–13% have hematological malignancies [24,26,31]. In
contrast, the proportion of HIV-related PML cases in
Japan was approximately 33%, which is much lower than
that in the USA. The difference in the ratios of HIV-
related PML between these two countries must be inter-
preted based on the epidemiological status of HIV
infection. According to the latest data from the Joint
United Nations Programme on HIV/AIDS, World
Health Organization [32], the prevalence of HIVtients positive or negative for CSF JCV
V-positive
T (n=27)
Proportion (%) of JCV-negative












Table 3 Characteristics of PML patients with a history of hematopoietic stem cell transplantation
Patient Age Sex Underlying disease Type of transplant Interval (Days) a
1 50 M Acute myeloid leukemia Allogeneic bone marrow 279
2 44 M Acute lymphoblastic leukemia Allogeneic bone marrow 442
3 42 M Aplastic anemia Allogeneic bone marrow 614
4 58 M Aplastic anemia Allogeneic bone marrow 493
5 43 M Acute myeloid leukemia Umbilical cord blood 450
6 16 M Hodgkin's lymphoma Autologous bone marrow 285
7 61 M Non-Hodgkin's lymphoma Autologous peripheral blood 775
8 52 M Multiple myeloma Autologous peripheral blood 833
M, male.
a Days between transplantation and the initial testing for JCV DNA in CSF specimens.
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fold higher than that in Japan (< 0.1%). Thus, it is
reasonable to suppose that the relatively low proportion
of HIV-related PML in Japan is associated the low pre-
valence of HIV infection. As a large proportion of HIV-
infected individuals in Japan are male [32], it is also
reasonable that the sex ratio of HIV-related PML
showed a predominance of males.
A notable finding of the present study is that
hematologic disorders are a main risk factor for PML in
Japan. Five of 19 patients in this group had received allo-
geneic HSCT, suggesting that this type of transplantation
is an important risk factor of PML. In the other 14 PML
cases, 11 individuals (patients 6–16) were administrated
with chemotherapeutic and / or immunosuppressive
agents for the treatment of hematologic malignancies.
Thus, it is likely that these therapies are associated with
the high incidence of PML cases in this category. The
present study also demonstrates that the majority of
PML patients with hematologic disorders are males.Table 4 Chemotherapy or immunosuppressive treatment in P
transplantation
Patient Age Sex Underlyin
9 78 M Non-Hodg
10 66 M Non-Hodg
11 72 F Non-Hodg
12 64 F Non-Hodg
13 77 M Adult T-ce
14 64 M Multiple m
15 67 M Chronic lym
16 71 M Primary m
17 62 M Non-Hodg
18 22 M Primary im
19 24 M Primary im
M, male; F, female; CPA, cyclophosphamide; THP, pirarubicin; VDS, vindesine; PSL, pr
dexamethasone; Bzb, bortezomib; NA, not administered.In contrast, the percentages of male patients with hema-
tologic malignancies were similar to or slightly higher
than those of females (leukemia, 59.1%; lymphoma,
52.9%; MM, 52.1%) according to the most recent statis-
tics from the National Database for Cancer Incidence in
Japan [33]. The reason for the male predominance
among PML patients with hematologic disorders remains
unknown. Further studies are needed on larger popula-
tions of PML patients to clarify the mechanism and sig-
nificance of this sexual dimorphism. However, these data
are thought to be beneficial for patients having similar
underlying diseases.
In 50 subjects with autoimmune disorders, 3 SLE
patients were diagnosed as having PML. These patients
had been treated with immunosuppressive agents,
such as tacrolimus, mesalazine, mycophenolate mofetil,
prednisolone, and / or cyclophosphamide, but not with
therapeutic antibodies. No PML cases were observed
among individuals with other types of autoimmune dis-
orders. In Japan, natalizumab and efalizumab are notML patients without hematopoietic stem cell
g disease Chemotherapeutic or
immunosuppressive agents
kin's lymphoma CPA, THP, VDS, PSL, R
kin's lymphoma CPA, DXR, VCR, PSL, R
kin's lymphoma CPA, DXR, VCR, PSL, THP, R
kin's lymphoma CPA, DXR, VCR, PSL, ETP
ll leukemia CPA, DXR, VCR, PSL






ednisolone; R, rituximab; DXR, doxorubicin; VCR, vincristine; ETP, etoposide; DEX,
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for the treatment of autoimmune disorders. Therefore,
increased awareness may be needed about the potential
for PML in accordance with the wide spread use of
therapeutic monoclonal antibodies in this country. It
was also shown that the occurrence of PML is uncom-
mon in individuals receiving solid-organ transplantation.
Among the total study population, only 10 subjects
underwent kidney, liver, or heart transplantation, and
PML developed in one liver-transplanted patient. As this
patient had suffered from common variable immuno-
deficiency, the association between the transplanta-
tion and PML remains unclear. This situation can be
explained by the limited number of patients, who under-
went organ transplantation, especially from brain dead
donors [34]. However, it is predicted that the risk of
PML will increase in accordance with the revision of the
transplantation law in 2010, which extends the availabil-
ity of transplantation therapy [35].Conclusions
The results of this study suggest that the internet-
assisted laboratory surveillance system might be a useful
strategy for elucidating the characteristics of PML on a
national level. The present database provides important
background information for the diagnosis and treatment
of patients with risk factors for PML in Japan.Additional files
Additional file 1: Figure S1. Schematic diagram of the standard DNA
and primer / probe sets for PCR testing. Yellow and grey lines represent
the sequences of the JCV genome and pBR322 vector within the
standard DNA (pJC1-4->pJCV), respectively. The numbers in the circle
correspond to the nucleotide positions within the JCV genome. Three
primer / probe sets detect the JCV T and VP1 genes and the boundary
sequence of the JCV genome and pBR322 (green, red, and blue,
respectively).
Additional file 2: Figure S2. Examples of real-time PCR amplifications.
Three real-time PCR assays were designed to detect the JCV T (A) and
VP1 (B) sequences and the contamination of samples with standard DNA
(C). The reactions were performed in the absence or presence of
standard DNA (2.0 x 108 to 0.8 copies per reaction). Relative fluorescence
is plotted against cycle number. These PCR assays were capable of
detecting at least 4 copies of JCV DNA per reaction under the same
conditions. The data are representative of three independent
experiments.Abbreviations
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